|
We are currently conducting CNS studies for the treatments of Alzheimer’s Disease (AD), Diabetic Peripheral Neuropathy (DPN), Epilepsy, Multiple Sclerosis (MS), and Parkinson’s Disease (PD).
Please click on the links to the right for more information on our current enrolling studies.
Alzheimer's Disease (ELN301/302):
This research study is for patients 50-88 years of age diagnosed with probable mild to moderate Alzheimer's disease. You must have a caregiver that is willing to be involved in the study. This study lasts 83 weeks with 15 visits. You will receive 6 infusions every 13 weeks. This research study compares the safety and effectiveness of 3 doses of an investigational drug to placebo. The investigational drug is aimed at slowing the progression of the disease. There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com.
Return to the list of our services
Alzhiemer's Disease (CONCERT - DIM18):
This research study is for subjects 50 years of age and older diagnosed with probable mild to moderate Alzheimer’s disease (AD). Participants must have a caregiver that is willing to be involved in the study. This study is 1 year with up to 10 visits. All patients will have the opportunity to enter into an Open Label Extension study at the end of the 12 months. The study will examine the potential increased benefits of an investigational treatment in patients who are currently taking Aricept. Study participants will be randomly assigned to one of three treatment groups: dimebon 20mg three times per day, dimebon 5mg three times per day or placebo (an inactive look alike substance). Patients must be on Aricept 10mg for 4 months before screening and can not be taking any other Alzheimer’s medications (Namenda, Exelon, or Razadyne). There is no cost to participate and participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com.
Return to the list of our services
Epilepsy (A1096):
This research study is for people 18-65 years of age diagnosed with epilepsy with partial-onset seizures. Currently taking 1-3 antiepileptic drugs. Volunteers are needed to participate in this clinical research study of an approved medication for add-on treatment of epilepsy. The study up to 19 weeks with at least 7 visits. You will have a Visual Field Test performed during the study. There is no cost to participate and the participation is voluntary. There is some reimbursement for time and travel available. After you complete the study, epilepsy medications prescribed by the study doctor will be provided to you at no cost for six months. Contact Clinical Trials, Inc. at 501-227-6179 to see if you might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
Epilepsy (SP902/904):
This study is for patients 16-70 years of age diagnosed with epilepsy with partial-onset seizures with or without secondary generalization. Must be on a stable dose (28 days) of 1 or 2 AED's (anti-epileptic drugs). Must weigh >88lbs and cannot have been in any other trial in the last 2 months. This study lasts up to 30 weeks with visits every 1-4 weeks with a total of up to 14 clinic visits and a possible extension study lasting 2 years. This study tests the effectiveness and safety of an investigational drug as monotherapy (other AEDs will be discontinued). There is no cost to participate and the patient participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com.
Return to the list of our services
Epilepsy (K826):
This research study is for patients ages 2 and older diagnosed with epilepsy experiencing acute repetitive seizures (ARS) that require intermittent medical intervention. The patient must weight more than 13 lbs and no more than 300 lbs. Must be on a stable regimen of AEDs for at least 2 weeks, vagal nerve stimulation (VNS) is allowed if implanted for at least 6 months and stable for 2 weeks. Must have experienced at least 2 episodes of ARS in the last year, one of which must have occurred in the last 6 months. Must have a reliable caregiver that is 18 or older and can administer study drug and monitor patient seizures and respiratory rate (2 hour training provided). The length of this study is up to 18 months, visits are based on frequency of ARS episodes and study drug use. There is no cost to participate and participation is voluntary. There is some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
Parkinson's Disease (Impax006):
This research study is for patients diagnosed with Parkinson's disease at 30 years of age or older. Must be taking carbidopa-levodopa (Sinemet) at least 4 times a day and on a stable dose for 4 weeks. Must be experiencing "off" periods for at least 2.5 hours during the day. Cannot have had a pallidotomy or deep brain stimulation surgery for Parkinson's. This study is 22 weeks with 9 office visits. This study is evaluating the safety and effectiveness of an investigational drug which may reduce "off" periods. IPX066 is an investigational form of an oral medication for Parkinson's disease. There is no cost to participate and the patient/caregiver participation in voluntary. There may be some reimbursement for time and travel available. Contact Clinical Trials, Inc. at 501-227-6179 to see if you or a loved one might qualify. For email inquiries, contact info@clinicaltrialsinc.com
Return to the list of our services
|
